ARSANIS
Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build and advance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets. The company’s lead clinical p... rogram, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus. Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
ARSANIS
Industry:
Biotechnology Health Care Life Science
Founded:
2010-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.arsanis.com
Total Employee:
11+
Status:
Closed
Contact:
431-799-0117
Email Addresses:
[email protected]
Total Funding:
120.27 M USD
Technology used in webpage:
Domain Not Resolving Euro IPv6 Cloudflare Hosting Cloudflare DNS
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
SV Health Investors
SV Health Investors investment in Series D - Arsanis
OrbiMed
OrbiMed investment in Series D - Arsanis
EMBL Ventures
EMBL Ventures investment in Series D - Arsanis
Google Ventures
Google Ventures investment in Series D - Arsanis
Polaris Partners
Polaris Partners investment in Series D - Arsanis
Alexandria Venture Investments
Alexandria Venture Investments investment in Series D - Arsanis
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Series D - Arsanis
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Grant - Arsanis
SV Health Investors
SV Health Investors investment in Series C - Arsanis
SV Health Investors
SV Health Investors investment in Debt Financing - Arsanis
Official Site Inspections
http://www.arsanis.com
- Host name: 104.21.66.39
- IP address: 104.21.66.39
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Arsanis"
Arsanis - Crunchbase Company Profile & Funding
Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with …See details»
Arsanis - Devex
Arsanis was co-founded in 2010 by three infectious disease and industry veterans: Eszter Nagy, MD, PhD, Chief Scientific Officer of Arsanis and Managing Director of Arsanis Biosciences …See details»
Arsanis, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Visram, Arsanis Biosciences GmbH: Employee, Salary. A. Badarau, Arsanis Biosciences GmbH: Employee, Salary. S. A. Van Wart, Arsanis, Inc.: Research Contractor, Research support. ...See details»
Arsanis - VentureRadar
Arsanis, Inc. is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The …See details»
Arsanis - Contacts, Employees, Board Members, Advisors & Alumni
Arsanis has 6 current employee profiles, including Founder and Chairman Tillman Gerngross. Arsanis has 4 board members and advisors, including Claudio Nessi . ContactsSee details»
Arsanis Company Profile 2024: Valuation, Investors, Acquisition
Arsanis was founded in 2010. Where is Arsanis headquartered? Arsanis is headquartered in Waltham, MA. What is the size of Arsanis? Arsanis has 39 total employees. What industry is …See details»
Arsanis - Profile
Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. Monoclonal antibodies have transformed the …See details»
Arsanis - Funding, Financials, Valuation & Investors - Crunchbase
Arsanis is registered under the ticker NASDAQ:ASNS . Their stock opened with $10.00 in its Nov 15, 2017 IPO. Stock Symbol NASDAQ:ASNS ; Valuation at IPO $136M; Money Raised at IPO …See details»
Arsanis, Inc. Asset Profile | Preqin
Founded in 2010 and based in Massachusetts, United States, Arsanis, Inc. is a biopharmaceutical company that develops human monoclonal antibody therapeutics for the treatment of critical …See details»
Company Arsanis Inc Nasdaq - MarketScreener.com
Jun 30, 2014 Business description: Arsanis Inc X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel …See details»
Arsanis - Company Profile - Tracxn
Nov 26, 2024 Arsanis - Developer of monoclonal antibodies to treat infectious diseases. Public Company. Raised a total funding of $90.5M over 11 rounds from 11 investors. Founded by …See details»
Working At Arsanis: Company Overview and Culture - Zippia
Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences …See details»
Arsanis - Golden
Arsanis. A company developing targeted monoclonal antibody immunotherapies for the treatment of infectious diseases. Overview Structured Data Issues Contributors Activity. Contents. …See details»
Arsanis Inc: Business Model, SWOT Analysis, and Competitors 2024
Jan 21, 2024 The company was founded by Dr. Eszter Nagy, Dr. Tillman Gerngross, and Dr. Errik Anderson, who continue to hold ownership interests in the organization. The recent …See details»
Arsanis | Scientist.com
Arsanis 2 Helmut-Qualtinger-Gasse Wien, Wien, 1030 Austria: Get started If your organization has a Scientist.com marketplace, you can log in here to order products and services directly. If …See details»
Arsanis Company Overview, Contact Details & Competitors | LeadIQ
Dec 4, 2017 Learn more about Arsanis's company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ. Book a demo today. ... X4 has continued …See details»
Arsanis, Inc. - Cruelty Free Investing
Arsanis, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products, services, research and therapies. …See details»
Arsanis and X4 Pharmaceuticals Announce Merger
Nov 28, 2018 Arsanis and privately-held X4 Pharmaceuticals have entered into a definitive merger agreement under which X4 Pharmaceuticals is expected to merge with a wholly-owned …See details»
How New Solutions from Arsanis Affect the Treatment of Diseases
Arsanis' innovative solutions are reshaping the way we approach the treatment of diseases, offering more precise, effective, and safer options for patients. By focusing on targeted …See details»
What is Arsanis? Company Culture, Mission, Values | Glassdoor
See what employees say it's like to work at Arsanis. Salaries, reviews, and more - all posted by employees working at Arsanis.See details»